Pharmaceutical giant acquires biopharmaceutical researcher in move to diversify beyond current blockbuster drugs. Schering-Plough shares soar 14 percent; Merck dips 7.7 percent.
|
Life sciences investment firm shells out $30M for clinical trial of drug in stock and royalty deal.
|
Earnings for drug maker’s fourth quarter are flat.
|
Two treatments for Parkinson’s found to harm heart valves.
|
Indian firm receives U.S. approval to market Simvastatin, a rival to Merck’s Zocor.
|
Company shares plummet in the wake of dissapointing trials for an experimental cholesterol drug.
|
The greatest thing since insulin? Inhaled insulin.
|
Experimental cholesterol medication also raises blood pressure.
|
Federal court denies a rehearing on Lipitor patent case.
|
The drug company agrees to acquire the U.K.-based vaccine maker.
|
Healthcare unit acquires Swedish drug development equipment maker as Pfizer divests holdings.
|
Red Herring magazine’s biosciences news briefs for the week of June 19, 2006.
|
Traditionally the home turf of biotech companies, big pharma is making strides in developing new cancer drugs.
|
Resource-strapped TV stations are using ‘news’ videos sponsored by big business and made by PR firms.
|
Agency’s rejection of high-dose insomnia pill rips stock and leaves Pfizer deal in flux.
|
Pharma supply chain software maker raises second round from Pfizer, Bethesda Partners, and existing investors.
|
A leading medical journal says big pharma over-hypes and even makes up diseases for profit.
|
Drug developer Merrimack grabs $65M; Lung device maker Spiration gets $13.4M; Treating colon cancer with Celebrex.
|
The race is on to serve world’s largest diabetics population.
|
A study claims Celebrex should not receive preferential treatment over Vioxx.
|
Page
1
of
5
|